Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on May 15, 2019. The report details a strategic pivot announced on the same date to accelerate the development of the Orion Visual Cortical Prosthesis System while reducing focus on the existing Argus II product line.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the Form 10-Q for the period ended March 31, 2019, for details regarding one-time impairment charges, severance costs, and other related financial activities.
Material Changes and Strategic Actions
- Product Strategy: The Company plans to suspend production of Argus II systems while continuing to implant devices using existing inventory.
- Resource Allocation: Focus is shifting to the Orion system, which targets blindness from causes including glaucoma, diabetic retinopathy, and retinitis pigmentosa.
- Workforce Changes: The Company intends to hire over 25 experienced research and development positions.
- Cost Reduction: Commercial expenses will be reduced.
- Regulatory Environment: Management noted positive developments at the Center for Medicare and Medicaid Services (CMS) regarding funding for FDA breakthrough devices like Orion.
Guidance, Risks, and Contingencies
Management commentary highlights encouraging results from the Orion early feasibility study. The filing explicitly directs investors to the Risk Factors section of the concurrent Form 10-Q for a description of one-time impairment charges and severance costs associated with this strategic refinement. No specific forward-looking financial guidance is included in this text.
Investor Verification Checklist
- Review the Form 10-Q filed on May 15, 2019, for specific figures on impairment charges and severance costs.
- Verify the timeline for the suspension of Argus II production and the status of existing inventory.
- Monitor updates on CMS funding decisions for FDA breakthrough devices.
- Assess the progress of the Orion early feasibility study results.